China Prazosin Market Trends, Future Outlook, COVID-19 Impact Analysis, Forecast 2022-2028

China prazosin market is estimated to decline during the forecast period. China is among the emerging nations facing a burden of the continuous increase in high blood pressure. Lack of physical activity, obese population, alcohol consumption, and smoking are some of the major factors that lead to the increasing incidences of high blood pressure. The rising aging population may further increase the risk of hypertension in China. As per the United Nations (UN), in 2019, the percentage of the population aged 65 years and over in the country was 11.5%, which is expected to reach 16.9% by 2030. With the age, arteries get stiffer and thereby blood pressure goes up. Hypertension is one of the primary modifiable risk factors for CVD and its prevalence as well as severity both increase with age. However, the discontinuation of prazosin drugs due to various side effects further projected to decline the market growth during the forecast period.

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/china-prazosin-market

China prazosin market is segmented on the basis of application into cardiovascular disease, neurological syndromes, prostate disorders, and kidney disorders. The CVD segment accounted for the significant share in the China prazosin market. CVDs claim to take more lives each year than all forms of cancer and chronic lower respiratory diseases altogether. Thus, Prazosin is one of the treatments used for CVD mainly high BP and strokes. For instance, Minipress is specified for the treatment of hypertension, to control BP. Lowering blood pressure decreases the risk of fatal and nonfatal cardiovascular events, mainly strokes and myocardial infarction.  

The companies which are contributing to the growth of the China prazosin market include Ajinomoto Co., Inc., Standard Chem and Pharmaceuticals Co. Ltd., Sun Pharmaceuticals Industries Ltd., Merck KGaA, Mylan N.V., Pfizer Inc., and others. The market players are considerably contributing to the market by the adoption of various strategies including new product launch, merger, and acquisition, collaborations to stay competitive in the market.

China Prazosin Market- Segmentation

By Application

·         Cardiovascular Disease(CVD)

·         Neurological Syndromes 

·         Prostate Disorders

·         Kidney Disorders

A full report of China Prazosin Market is available at: https://www.omrglobal.com/industry-reports/china-prazosin-market

Company Profiles

·         Ajinomoto Co., Inc.

·         Johnlee Pharmaceuticals Pvt. Ltd.

·         Merck KGaA

·         Pfizer Inc.

·         R&D Systems Inc.

·         Renata Ltd.

·         Mylan N.V.

·         Standard Chem and Pharmaceuticals Co. Ltd.

·         Sun Pharmaceuticals Industries Ltd.

·         Teva Pharmaceuticals Industries Ltd.

Reasons to Buying From us –

1.       We cover more than 15 major industries, further segmented into more than 90 sectors.

2.       More than 120 countries are for analysis.

3.       Over 100+ paid data sources mined for investigation.

4.       Our expert research analysts answer all your questions before and after purchasing your report.

 

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

 

Media Contact:

Contact Person: Mr. Anurag Tiwari

Email: anurag@omrglobal.com

Contact no: +91 780-304-0404

Company Name: Orion Market Research